{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:27Z","timestamp":1786982127284,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T00:00:00Z","timestamp":1401926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s11906-014-0453-9","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T18:24:40Z","timestamp":1401906280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Baroreflex Activation: from Mechanisms to Therapy for Cardiovascular Disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Radu","family":"Iliescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionut","family":"Tudorancea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Lohmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,5]]},"reference":[{"key":"453_CR1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/HYPERTENSIONAHA.108.119859","volume":"57","author":"TE Lohmeier","year":"2011","unstructured":"Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation. Mechanisms and potential for hypertension therapy. Hypertension. 2011;57:880\u20136.","journal-title":"Hypertension"},{"key":"453_CR2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension. 2008;51:1403\u201319.","journal-title":"Hypertension"},{"key":"453_CR3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacc.2010.03.089","volume":"56","author":"IJM Scheffers","year":"2010","unstructured":"Scheffers IJM, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension. J Am Coll Cardiol. 2010;56:1254\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"453_CR4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","volume":"58","author":"JD Bisognano","year":"2011","unstructured":"Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal trial. J Am Coll Cardiol. 2011;58:765\u201373. The first randomized controlled trial investigating safety and efficacy of baroreflex activation therapy as treatment for resistant hypertension.","journal-title":"J Am Coll Cardiol"},{"key":"453_CR5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jash.2012.01.003","volume":"6","author":"GL Bakris","year":"2012","unstructured":"Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal trial. J Am Soc Hypertens. 2012;6:152\u20138.","journal-title":"J Am Soc Hypertens"},{"key":"453_CR6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","volume":"6","author":"UC Hoppe","year":"2012","unstructured":"Hoppe UC, Brandt M-C, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270\u20136.","journal-title":"J Am Soc Hypertens"},{"key":"453_CR7","unstructured":"Gasser JP, Bisognano JD. Baroreflex activation therapy in hypertension. J Hum Hypertens. 2014;1\u20136."},{"key":"453_CR8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","volume":"311","author":"JN Cohn","year":"1984","unstructured":"Cohn JN, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med. 1984;311:819\u201323.","journal-title":"N Engl J Med"},{"key":"453_CR9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejvs.2006.11.025","volume":"33","author":"JHM Tordoir","year":"2007","unstructured":"Tordoir JHM, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for treatment of resistant hypertension. Eur J Vasc Endovasc Surg. 2007;33:414\u201321.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"453_CR10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/01.HYP.0000111837.73693.9b","volume":"43","author":"TE Lohmeier","year":"2004","unstructured":"Lohmeier TE, Irwin ED, Rossing MA, et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306\u201311.","journal-title":"Hypertension"},{"key":"453_CR11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1161\/HYPERTENSIONAHA.107.087874","volume":"49","author":"TE Lohmeier","year":"2007","unstructured":"Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307\u201314.","journal-title":"Hypertension"},{"key":"453_CR12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2310\/6670.2007.00024","volume":"15","author":"J Schmidli","year":"2007","unstructured":"Schmidli J, Savolainen H, Eckstein F, et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular. 2007;15:63\u20139.","journal-title":"Vascular"},{"key":"453_CR13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-323-03961-1.50027-1","volume-title":"Comprehensive hypertension","author":"TE Lohmeier","year":"2007","unstructured":"Lohmeier TE, Drummond HA. The baroreflex in the pathogenesis of hypertension. In: Lip GYH, Hall JE, editors. Comprehensive hypertension. New York: Elsevier; 2007. p. 265\u201379."},{"key":"453_CR14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00007.2009","volume":"90","author":"SC Malpas","year":"2010","unstructured":"Malpas SC. Sympathetic nervous system activity and its role in the development of cardiovascular disease. Physiol Rev. 2010;90:513\u201357.","journal-title":"Physiol Rev"},{"key":"453_CR15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/HYPERTENSIONAHA.109.140665","volume":"55","author":"K Heusser","year":"2010","unstructured":"Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619\u201326.","journal-title":"Hypertension"},{"key":"453_CR16","doi-asserted-by":"crossref","first-page":"H402","DOI":"10.1152\/ajpheart.00372.2010","volume":"299","author":"TE Lohmeier","year":"2010","unstructured":"Lohmeier TE, Iliescu R, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010;299:H402\u20139. Shows that chronic baroreflex activation has sustained effects to suppress central sympathetic outflow and lower arterial pressure without activating the renin-angiotensin system.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"453_CR17","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.109.128884","volume":"53","author":"TE Lohmeier","year":"2009","unstructured":"Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension. 2009;53:833\u20138.","journal-title":"Hypertension"},{"key":"453_CR18","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1152\/japplphysiol.00552.2012","volume":"113","author":"TE Lohmeier","year":"2012","unstructured":"Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation. J Appl Physiol. 2012;113:1652\u20138.","journal-title":"J Appl Physiol"},{"key":"453_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1152\/physrev.1997.77.1.75","volume":"77","author":"GF DiBona","year":"1997","unstructured":"DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75\u2013197.","journal-title":"Physiol Rev"},{"key":"453_CR20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00583539","volume":"413","author":"H Ehmke","year":"1989","unstructured":"Ehmke H, Persson PB, Fischer S, et al. Resetting of pressure-dependent renin release by intrarenal \u03b11-adrenoceptors in conscious dogs. Pflugers Arch. 1989;413:261\u20136.","journal-title":"Pflugers Arch"},{"key":"453_CR21","first-page":"E57","volume":"257","author":"HM Yang","year":"1989","unstructured":"Yang HM, Lohmeier TE, Kivlighn SD, et al. Sustained increases in plasma epinephrine concentration do not modulate renin release. Am J Physiol. 1989;257:E57\u201364.","journal-title":"Am J Physiol"},{"key":"453_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.111.185074","volume":"59","author":"TE Lohmeier","year":"2012","unstructured":"Lohmeier TE, Iliescu R, Liu B, et al. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012;59:331\u20138. Provides insight into the mechanisms that account for abolition of hypertension and suppression of renin secretion and GFR during chronic activation of the baroreflex in dogs with obesity-induced hypertension.","journal-title":"Hypertension"},{"key":"453_CR23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.HYP.0000187011.44201.2e","volume":"46","author":"TE Lohmeier","year":"2005","unstructured":"Lohmeier TE, Dwyer TM, Hildebrandt DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46:1194\u2013200.","journal-title":"Hypertension"},{"key":"453_CR24","doi-asserted-by":"crossref","first-page":"A354","DOI":"10.1161\/hyp.62.suppl_1.A354","volume":"62","author":"TE Lohmeier","year":"2013","unstructured":"Lohmeier TE, Liu B, Georgakopoulos D, et al. Cardiovascular responses to chronic baroreflex activation in aldosterone hypertension. Hypertension. 2013;62:A354.","journal-title":"Hypertension"},{"key":"453_CR25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.113.01159","volume":"61","author":"T Alnima","year":"2013","unstructured":"Alnima T, de Leeuw PW, Tan ES, et al. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension. Hypertension. 2013;61:1334\u20139. This study reports an initial modest non-progressive decrease in eGFR in association with the antihypertensive response to 12\u00a0months of baroreflex activation therapy in patients with resistant hypertension. There were no changes in eGFR during baroreflex activation in patients in the lowest baseline eGFR category (<60\u00a0mL\/min).","journal-title":"Hypertension"},{"key":"453_CR26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/HYPERTENSIONAHA.112.193607","volume":"60","author":"R Iliescu","year":"2012","unstructured":"Iliescu R, Irwin ED, Georgakopoulos D, Irwin ED, et al. Renal responses to chronic suppression of central sympathetic outflow. Hypertension. 2012;60:749\u201356.","journal-title":"Hypertension"},{"key":"453_CR27","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00208.2003","volume":"286","author":"SC Thomson","year":"2004","unstructured":"Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular hyperfiltration. Am J Physiol Renal Physiol. 2004;286:F8\u201315.","journal-title":"Am J Physiol Renal Physiol"},{"key":"453_CR28","first-page":"S258","volume":"10","author":"JE Hall","year":"1999","unstructured":"Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol. 1999;10:S258\u201365.","journal-title":"J Am Soc Nephrol"},{"key":"453_CR29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685\u201393.","journal-title":"Arch Intern Med"},{"key":"453_CR30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.109.134023","volume":"54","author":"K Wustmann","year":"2009","unstructured":"Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530\u20136.","journal-title":"Hypertension"},{"key":"453_CR31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10741-010-9179-1","volume":"16","author":"PJ Schwartz","year":"2011","unstructured":"Schwartz PJ, De Ferrari GM. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev. 2011;16:101\u20137.","journal-title":"Heart Fail Rev"},{"key":"453_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2011.00121","volume":"2","author":"CM Hildreth","year":"2012","unstructured":"Hildreth CM. Prognostic indicators of cardiovascular risk in renal disease. Front Physiol. 2012;2:1\u20136.","journal-title":"Front Physiol"},{"key":"453_CR33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.CIR.90.2.878","volume":"90","author":"H Tsuji","year":"1994","unstructured":"Tsuji H, Venditti FJ, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90:878\u201383.","journal-title":"Circulation"},{"key":"453_CR34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/qjmed\/hci018","volume":"98","author":"MJ Reed","year":"2005","unstructured":"Reed MJ, Robertson CE, Addison PS. Heart rate variability measurements and the prediction of ventricular arrhythmias. Quart J Med. 2005;98:87\u201395.","journal-title":"Quart J Med"},{"key":"453_CR35","doi-asserted-by":"crossref","first-page":"H630","DOI":"10.1152\/ajpheart.00642.2001","volume":"282","author":"S Beske","year":"2002","unstructured":"Beske S, Alvarez GE, Ballard TP, et al. Reduced cardiovagal gain in visceral obesity: implications for the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2002;282:H630\u20135.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"453_CR36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.HYP.36.4.538","volume":"36","author":"G Grassi","year":"2000","unstructured":"Grassi G, Seravalle G, Dell\u2019Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538\u201342.","journal-title":"Hypertension"},{"key":"453_CR37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1540-8167.2006.00680.x","volume":"18","author":"G Pietrasik","year":"2007","unstructured":"Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007;18:87\u201395.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"453_CR38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ahj.2007.10.004","volume":"155","author":"N Wanahita","year":"2008","unstructured":"Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity\u2014results of meta-analysis. Am Heart J. 2008;155:310\u20135.","journal-title":"Am Heart J"},{"key":"453_CR39","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","volume":"292","author":"TJ Wang","year":"2004","unstructured":"Wang TJ, Parise H, Levy D, D\u2019Agostino Sr RB, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. J Am Med Assoc. 2004;292:2471\u20137.","journal-title":"J Am Med Assoc"},{"key":"453_CR40","doi-asserted-by":"crossref","first-page":"H1080","DOI":"10.1152\/ajpheart.00464.2013","volume":"305","author":"R Iliescu","year":"2013","unstructured":"Iliescu R, Tudorancea I, Irwin ED. Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension. Am J Physiol Heart Circ Physiol. 2013;305:H1080\u20138. Based on continuous 24-hour recordings of spontaneous fluctuations in arterial pressure and heart rate, this study shows that chronic baroreflex activation restores impaired cardiac baroreflex sensitivity and heart rate variability in obesity hypertension.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"453_CR41","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","volume":"82","author":"GS Francis","year":"1990","unstructured":"Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of left ventricular dysfunction (SOLVD). Circulation. 1990;82:1724\u20139.","journal-title":"Circulation"},{"key":"453_CR42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD The","year":"1991","unstructured":"The SOLVD. investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"453_CR43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"II Cibis","year":"1999","unstructured":"Cibis II. Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBUS II). Lancet. 1999;353:9\u201313.","journal-title":"Lancet"},{"key":"453_CR44","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","volume":"103","author":"P Lechat","year":"2001","unstructured":"Lechat P. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428\u201333.","journal-title":"Circulation"},{"key":"453_CR45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10741-010-9209-z","volume":"16","author":"HN Sabbah","year":"2011","unstructured":"Sabbah HN, Ilsar I, Zaretsky A, et al. Vagus nerve stimulation in experimental heart failure. Heart Fail Rev. 2011;16:171\u20138.","journal-title":"Heart Fail Rev"},{"key":"453_CR46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/CIRCHEARTFAILURE.109.873968","volume":"2","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail. 2009;2:692\u20139.","journal-title":"Circ Heart Fail"},{"key":"453_CR47","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.CIR.0000105721.71640.DA","volume":"109","author":"M Li","year":"2004","unstructured":"Li M, Zheng C, Sato T, et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004;109:120\u20134.","journal-title":"Circulation"},{"key":"453_CR48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/HYPERTENSIONAHA.107.095216","volume":"50","author":"IH Zucker","year":"2007","unstructured":"Zucker IH, Hackley JF, Cornish KG, et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension. 2007;50:904\u201310.","journal-title":"Hypertension"},{"key":"453_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.110.955013","volume":"4","author":"HN Sabbah","year":"2011","unstructured":"Sabbah HN, Gupta RC, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail. 2011;4:65\u201370. Shows that chronic baroreflex activation improves left ventricular function and partially reverses left ventricular remodeling both globally and at the cellular and molecular levels, and increases the threshold for lethal ventricular arrhythmias in dogs with advanced heart failure.","journal-title":"Circ Heart Fail"},{"key":"453_CR50","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2010.11.048","volume":"57","author":"JD Bisognano","year":"2011","unstructured":"Bisognano JD, Kaufmann CL, Bach DS. Improved cardiac structure and function with chronic treatment using an inflatable device in resistant hypertension. J Am Col Cardiol. 2011;57:1787\u20138.","journal-title":"J Am Col Cardiol"},{"key":"453_CR51","volume":"128","author":"E Gronda","year":"2013","unstructured":"Gronda E, Seravalle G, Brambilla G. Chronic baroreflex activation reduces sympathetic tone and improves clinical outcomes in reduced-ejection fraction heart failure. Circulation. 2013;128, A16137.","journal-title":"Circulation"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-014-0453-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-014-0453-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-014-0453-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-014-0453-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T19:55:05Z","timestamp":1649188505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-014-0453-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,5]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1007\/s11906-014-0453-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,5]]},"assertion":[{"value":"5 June 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<b>Conflict of Interest<\/b> Radu Iliescu and Ionut Tudorancea declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Thomas E. Lohmeier has received consulting fees from CVRx, Inc., and research support from National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"<b>Human and Animal Rights and Informed Consent<\/b> This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}}],"article-number":"453"}}